CTLA4 and cancer: In this work, we demonstrate that immune regulatory networks of NO and CTLA-4 can be therapeutically ameliorated for cancer immunotherapy by a thermosensitive biomaterial-based hydrogel system for controlled locoregional delivery of both a NO-donor and monoclonal antibody (mAb) antagonizing CTLA-4 (aCTLA-4).